10x Genomics revenue and financials
$80.66Change from previous close: −17.47%Absolute change: −$17.08
In the fiscal year ended December 2025, 10x Genomics reported revenue of $642.82M (+5.25% year over year). The net loss was $43.54M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.25%
- 2025 vs 2024
- Net margin
- -6.8%
- 2024: -29.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 136 | 6.7 | -15.2 | -33.6 | -21.4 | -218 | 34.6 | -76.4 | -10.7 |
| Depreciation and amortization | 36.2 | 35.9 | 35.5 | 25.4 | 21.1 | 14.0 | 7.1 | 3.9 | 4.3 |
| Capital expenditure | -5.9 | -12.4 | -48.6 | -132 | -101 | -36.7 | -42.7 | -6.3 | -3.8 |
| Investing cash flow | -13.4 | -32.6 | 133 | -351 | -107 | — | — | — | — |
| Financing cash flow | 6.8 | 10.9 | 13.7 | 15.8 | 35.3 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | -0.1 |
| Debt repaid | — | — | -5.8 | -5.4 | -5.0 | — | — | — | — |
| Effect of exchange rates | 0.5 | -0.2 | -0.0 | -0.0 | 0.2 | — | — | — | — |
| Net change in cash | 130 | -15.2 | 132 | -369 | -92.6 | — | — | — | — |
| Free cash flow | 130 | -5.7 | -63.8 | -165 | -123 | — | — | — | — |
| Levered free cash flow | 148 | 59.2 | 27.6 | -92.7 | -67.0 | — | — | — | — |